Helixgate

Helixgate

Uncategorized

Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut

Published

on

A trio of biotechs priced their IPOs on Thursday into Friday morning, setting the stage for their public trading debuts with more than $850 million combined.

Seaport Therapeutics, Hemab Therapeutics and Avalyn Pharma are the …

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

PFAS is still in some infant formula

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Too much news yesterday, so here’s a link to a late-breaking story that the FDA has chosen Vinay Prasad’s interim successor.

Read the rest…

Read More

Published

on

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Too much news yesterday, so here’s a link to a late-breaking story that the FDA has chosen Vinay Prasad’s interim successor.

Read the rest…

Read More

Continue Reading

Uncategorized

Summit slips on ivonescimab’s apparent interim miss in sign of investor frustration

Summit slips on ivonescimab’s apparent interim miss in sign of investor frustration

Published

on

Summit Therapeutics’ stock price {$SMMT} tumbled nearly 20% after the closing bell Thursday afternoon, following an apparent statistical miss in part of a Phase 3 trial for its cancer drug ivonescimab.

In patients with a …​ ​Read More

Continue Reading

Uncategorized

Amgen positions MariTide as potential ‘best monthly’ obesity drug

Published

on

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own investigational obesity asset MariTide, which could open up monthly or more infrequent dosing schedules.

Continue Reading
Advertisement

Trending